NCT02499159 - Pain Management in Response to Exparel vs. Standard Bupivicaine | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions

Pain

Interventions

DRUG

Liposomal Bupivicaine

266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.

DRUG

0.25% standard bupivicaine

standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.

Trial Locations (2)

Cardiac, Vascular, and Thoracic Surgery Associates, Falls Church

Inova Fairfax Hospital, Falls Church